Specialty code 183500000X · Santa Rosa, CA
NPI
1235406695
Since 2011
Specialty
Specialty code 183500000X
Code 183500000X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
401 Bicentennial Way
Santa Rosa, CA, 95403
Phone (707) 393-4000
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$473K
2,463 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Danny D Kim prescribed most often to Medicare patients was Atorvastatin Calcium, with 331 prescriptions and refills. In total Danny D Kim wrote 2,463 Medicare prescriptions that cost $473K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-10-28.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Atorvastatin Calcium Generic | 331 | 1,103 | 146 | $4,117 |
| Metformin Hcl Er Metformin Hcl | 247 | 817 | 123 | $2,575 |
| Metformin Hcl Generic | 146 | 468 | 70 | $1,843 |
| Glipizide Generic | 140 | 458 | 72 | $1,731 |
| Humulin N Insulin Nph Human Isophane | 137 | 403 | 71 | $21K |
| Ozempic Semaglutide | 135 | 142 | 30 | $101K |
| Jardiance Empagliflozin | 133 | 434 | 73 | $78K |
| Victoza 2-Pak Liraglutide | 117 | 124 | 34 | $75K |
| Ultra-Fine Nano Pen Needle Pen Needle, Diabetic | 112 | 271 | 59 | $2,376 |
| Liraglutide Generic | 94 | 97 | 31 | $68K |
| Glipizide Er Glipizide | 86 | 283 | 42 | $2,925 |
| Veo Insulin Syringe Syringe-Needle,insulin,0.5 Ml | 73 | 224 | 41 | $2,153 |
| Insulin Glargine-Yfgn Generic | 72 | 203 | 39 | $8,157 |
| Humulin R Insulin Regular, Human | 69 | 198 | 27 | $12K |
| Rosuvastatin Calcium Generic | 69 | 229 | 35 | $801 |
Brand drugs: 941 claims; generic drugs: 1,306 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Danny D Kim were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.